A.M. CHAULIN^1,2, Yu.V. GRIGORYEVA¹, D.V. DUPLYAKOV^1,2

¹Samara State Medical University, Samara

²Samara Regional Cardiology Dispensary, Samara

  Contact:

Chaulin A.M. ― postgraduate student of the Department of Hystology and Embryology

Address: 89 Chapaevskaya Str., Samara, Russian Federation, 443099, tel. +7-927-770-25-87, e-mail: alekseymichailovich22976@gmail.com

 Currently, comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases is a serious medical and social problem. There is a rapid increase in morbidity and mortality in these diseases.

The research object is modern publications devoted to the problem of comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases: common risk factors, pathophysiological mechanisms, and clinical diagnostic aspects.

The aim of the work is to provide an analytical review containing a comprehensive analysis of data on the relationship of chronic obstructive pulmonary disease and cardiovascular diseases.

The research method is a critical analysis of literature data and the summation of modern results of original research.

Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) have a significant number of common risk factors (smoking, inflammation, old age, oxidative stress, etc.) and pathogenetic mechanisms, between which complex interactions are noted.

Conclusion. The comorbidity of COPD and CVD is an important public health problem due to their rapid growth and the lack of optimal diagnostic and treatment strategies. These diseases have numerous common risk factors and pathophysiological mechanisms. Identification of risk factors and understanding of pathogenetic mechanisms may contribute to the search for new therapeutic targets and the improvement of treatment-and-prophylactic and diagnostic strategies.

Key words: comorbidity, chronic obstructive pulmonary disease, COPD, cardiovascular diseases, CVD.

(For citation: Chaulin A.M., Grigoryeva Yu.V., Duplyakov D.V.

Comorbidity: chronic obstructive pulmonary disease and cardiovascular diseases. Practical medicine. 2020. Vol. 18, №1, P. 26-31)

REFERENCES

1. Tarlovskaya E.I. Comorbidity and polymorbidity — a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiya, 2018, vol. 58 (S9), pp. 29-38 (in Russ.). DOI: 10.18087/cardio.2562.
2. Vertkin A.L., Rumyantsev M.A., Skotnikov A.S. Comorbidity. Klinicheskaya meditsina, 2012, vol. 90, no. 10, pp. 4-11 (in Russ.), available at: https://www.elibrary.ru/item.asp?id=18756166
3. Naumova L.A., Osipova O.N. Comorbidity: mechanisms of pathogenesis, clinical significance. Sovremennye problemy nauki i obrazovanie, 2016, no. 5, pp. 105 (in Russ.), available at: https://www.elibrary.ru/item.asp?id=27181728
4. Adeloye D., Chua S., Lee C., et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J. Glob Health, 2015, vol. 5 (2), 020415. DOI: 10.7189/jogh.05-020415
5. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, vol. 5 (9), pp. 691-706. DOI: 10.1016/S2213-2600(17)30293-X
6. Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, vol. 3 (8), pp. 631-639. DOI: 10.1016/S2213-2600(15)00241-6
7. Cazzola M., Rogliani P., Matera M.G. Cardiovascular disease in patients with COPD. Lancet Respir. Med, 2015, vol. 3 (8), pp. 593-595. DOI: 10.1016/S2213-2600(15)00279-9
8. Roversi S., Fabbri L.M., Sin D.D., et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am. J. Respir. Crit Care Med, 2016, vol. 194 (11), pp. 1319-1336. DOI: 10.1164/rccm.201604-0690SO.
9. Mullerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: systematic literature review. Chest, 2013, vol. 144 (4), pp. 1163-1178. DOI: 10.1378/chest.12-2847.
10. Grigor’eva N.Yu., Mayorova M.V., Koroleva M.E., Samolyuk M.O. Features of the formation and development of cardiovascular diseases in patients with chronic obstructive pulmonary disease. Terapevticheskiy arkhiv, 2019, vol. 91, no. 1, pp. 16-47 (in Russ.). DOI: 10.26442/00403660.2019.01.000027.
11. Lahousse L., Tiemeier H., Ikram M.A., Brusselle G.G. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir. Med, 2015, vol. 109 (11), pp. 1371-1380. doi: 10.1016/j.rmed.2015.07.014.
12. Morgan A.D., Sharma C., Rothnie K.J., et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann. Am. Thorac Soc, 2017, vol. 14 (5), pp. 754-765. doi: 10.1513/AnnalsATS.201611-932SR.
13. Brusselle G., Bracke K., De Pauw M. Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir Crit Care Med, 2017, vol. 195 (2), pp. 148-150. doi: 10.1164/rccm.201608-1712ED.
14. Belenkov Yu.N., Tsvetkova O.A., Privalova E.V. et al. Comorbidity of chronic obstructive pulmonary disease and cardiovascular disease: a place of therapy with modern β-blockers. Kardiologiya, 2019, vol. 59 (6), pp. 48-55 (in Russ.). DOI: 10.18087/cardio.2019.6.n458
15. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation, 2002, vol. 105 (9), pp. 1135-1143. DOI: 10.1161/hc0902.104353
16. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, vol. 59 (7), pp. 574-580. DOI: 10.1136/thx.2003.019588
17. de Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J, 2006, vol. 27 (5), pp. 902-907. DOI: 10.1183/09031936.06.00109605
18. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med, 2006, vol. 174 (8), pp. 867-874. DOI: 10.1164/rccm.200604-506OC
19. Man S.F., Connett J.E., Anthonisen N.R. et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax, 2006, vol. 61 (10), pp. 849-853. DOI: 10.1136/thx.2006.059808.
20. Marchetti N., Ciccolella D.E., Jacobs M.R., et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD, 2011, vol. 8 (2), pp. 60-65. doi: 10.3109/15412555.2011.558541.
21. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest, 2013, vol. 143 (3), pp. 798-807. doi: 10.1378/chest.12-0938.
22. Criner G.J., Connett J.E., Aaron S.D., et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med, 2014, vol. 370 (23), pp. 2201-2210. doi: 10.1056/NEJMoa1403086.
23. John M.E., Cockcroft J.R., McKeever T.M., et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int. J. Chron. Obstruct Pulmon. Dis, 2015, vol. 10, pp. 211-221. doi: 10.2147/COPD.S76061
24. Seidel D., Cheung A., Suh E.S., et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int. J. Tuberc Lung Dis, 2012, vol. 16 (8), pp. 1015-1019. doi: 10.5588/ijtld.12.0050.
25. Van Remoortel H., Hornikx M., Langer D., et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med, 2014, vol. 189 (1), pp. 30-38. doi: 10.1164/rccm.201307-1240OC.
26. Katajisto M., Kupiainen H., Rantanen P., et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int. J. Chron Obstruct. Pulmon Dis, 2012, vol. 7, pp. 743-755. doi: 10.2147/COPD.S35497.
27. Barnes P.J. Senescence in COPD and Its Comorbidities. Annu Rev. Physiol, 2017, vol. 79, pp. 517-539. doi: 10.1146/annurev-physiol-022516-034314.
28. Savale L., Chaouat A., Bastuji-Garin S., et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med, 2009, vol. 179 (7), pp. 566-571. doi: 10.1164/rccm.200809-1398OC.
29. Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit Care Med, 2006, vol. 174 (8), pp. 886-893. DOI: 10.1164/rccm.200509-1374OC
30. Tuder R.M., Yoshida T., Fijalkowka I., et al. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac Soc, 2006, vol. 3 (8), pp. 673-679. DOI: 10.1513/pats.200605-124SF
31. Benetos A., Okuda K., Lajemi M., et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension, 2001, vol. 37 (2 Pt 2), pp. 381-385. DOI: 10.1161/01.hyp.37.2.381
32. Violan C., Foguet-Boreu Q., Flores-Mateo G., et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One, 2014, vol. 9 (7), e102149. DOI:10.1371/journal. pone. 0102149.
33. Austin V., Crack P.J., Bozinovski S., et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin. Sci (Lond), 2016, vol. 130 (13), pp. 1039-1050. DOI: 10.1042/CS20160043.
34. Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can J. Cardiol, 2016, vol. 32 (5), pp. 634-641. DOI: 10.1016/j.cjca.2015.11.022.
35. Cohen A.J., Brauer M., Burnett R., et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet, 2017, vol. 389 (10082), pp. 1907-1918. doi: 10.1016/S0140-6736(17)30505-6.
36. Chaudary N., Geraci S.A. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J. Miss State Med. Assoc, 2014, vol. 55 (2), pp. 40-44. https://www.ncbi.nlm.nih.gov/pubmed/25771612
37. Chaulin A.M., Duplyakov D.V. An increase in cardiac troponins not associated with acute coronary syndrome. Part 1. Kardiologiya: novosti, mneniya, obuchenie, 2019, vol. 7 (2), pp. 13-23 (in Russ.). doi: 10.24411/2309-1908-2019-12002.
38. Chaulin A.M., Duplyakov D.V. An increase in cardiac troponins not associated with acute coronary syndrome. Part 2. Kardiologiya: novosti, mneniya, obuchenie, 2019, vol. 7 (2), pp. 24-35 (in Russ.). doi: 10.24411/2309-1908-2019-12003.
39. Chaulin A.M., Karslyan L.S., Grigor’eva E.V. et al. Clinical and diagnostic value of cardiomarkers in human biological fluids. Kardiologiya, 2019, vol. 59 (11), pp. 66-75 (in Russ.). DOI:10.18087/cardio.2019.11.n414.
40. Chaulin A.M., Karslyan L.S., Grigor’eva E.V. et al. Features of the metabolism of cardiac troponins (literature review). Kompleksnye problemy serdechno-sosudistykh zabolevaniy, 2019, vol. 8 (4), pp. 103-115 (in Russ.). DOI: 10.17802/2306-1278-2019-8-4-103-115
41. Vertkin A.L., Topolyanskiy A.V., Knorring G.Yu., Shamuilova M.M. Management of a patient with dyspnea on an outpatient basis. Consilium Medicum, 2019, vol. 21 (1), pp. 98-104 (in Russ.). DOI: 10.26442/20751753.2019.1.190279
42. Rothnie K.J., Smeeth L., Herrett E., et al. Closing the mortality gap after a myocardial linfarction in people with and without chronic obstructive pulmonary disease. Heart, 2015, vol. 101 (14), pp. 1103-1110. doi: 10.1136/heartjnl-2014-307251.
43. Lipworth B., Wedzicha J., Devereux G., et al. Beta-blockers in COPD: time for reappraisal. Eur. Respir. J, 2016, vol. 48 (3), pp. 880-888. doi: 10.1183/13993003.01847-2015
44. Gershon A., Croxford R., Calzavara A., et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern. Med, 2013, vol. 173 (13), pp. 1175-1185. doi: 10.1001/jamainternmed.2013.1016.
45. Dong Y.H., Lin H.H., Shau W.Y., et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax, 2013, vol. 68 (1), pp. 48-56. doi: 10.1136/thoraxjnl-2012-201926.